MEDTECH

Outcomes4Me Partners with Invitae to Offer Genetic Testing to Breast Cancer Patients

Outcomes4Me | October 12, 2021

Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to expand education and access to genetic testing to breast cancer patients and survivors. The collaboration leverages the strengths of Invitae, which supplies clinical grade genetic testing, and Outcomes4Me’s 360-degree, validated and evidence-based cancer support and treatment options via its free and easy-to-use app. Initially and currently available in the United States, patients can now receive genetic counseling through Invitae’s partnership with Genome Medical, get testing, and upload their results within the Outcomes4Me app.There is a misconception that genetic testing is only useful as a preventative tool prior to a cancer diagnosis. According to Outcomes4Me patient data, almost half of users (46 percent) who qualified for testing (based on NCCN Guidelines®) did not receive testing or did not know if they had received testing. However, genetic testing can provide insights that can help inform and refine precision therapy use and clinical treatment trial enrollment. In addition, genetic testing results can be used to help prevent recurrence and reduce incidence of other inherited cancers.

A cancer diagnosis is often overwhelming for patients and their families. Outcomes4Me demystifies cancer by providing the most up-to-date and validated research, support, and treatment options, all grounded in science and data and curated according to the patient’s specific diagnosis. Outcomes4Me partners with the researchers, doctors, and academics that set the rigorous standards of cancer care for all treatment providers, including the National Comprehensive Care Network® (NCCN®), Vanderbilt-Ingram Cancer Center (VICC) and Massachusetts General Hospital (MGH). The collaboration with Invitae expands access to genetic testing, a vitally important tool in the patient’s cancer care arsenal.

“Outcomes4Me is an indispensable platform for patients with breast cancer, giving them the personalized knowledge and access to timely new trials and targeted therapies that could lead to better health outcomes. By providing access to our comprehensive genetic testing and counseling services, Outcomes4Me is adding a valuable resource that will empower patients to advance their knowledge, understanding, and therefore, self-advocacy during treatment and survivorship.”

Ed Esplin, M.D., Ph.D., FACMG, FACP, Clinical Geneticist at Invitae
 
Unlike popular direct-to-consumer genetic testing services, which test for a few specific genetic variants for certain genes, Invitae provides state-of-the-art clinical grade next-generation sequencing-based (NGS) genetic testing that comprehensively analyses more than 80 genes, including all known mutations of the important BRCA1/BRCA2 genes. This comprehensive approach, combined with associated genetic counseling, not only provides insights for cancer patients, but also for family members who may be at risk.

“Our collaboration with Invitae reinforces Outcomes4Me’s mission to give patients back control. Because of this work with Invitae, our valued community now has rare direct access to a much-needed testing service. Outcomes4Me will proudly continue to democratize the best in cancer treatment, research, and support by removing barriers and bias in information flow.”

Maya R. Said, Sc. D., Founder and CEO of Outcomes4Me
 
About Invitae
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. 

About Outcomes4Me
Outcomes4Me is on a mission to improve health outcomes by empowering patients with understandable, relevant and evidence-based information. Outcomes4Me has developed a platform for shared decision-making between patients and providers. The platform harnesses regulatory-grade, real-world data and patient experiences generating deeper insights and better outcomes to improve care and accelerate research. The Outcomes4Me mobile app enables cancer patients to make decisions and take control of their care based on information that is personalized to their specific condition, including finding treatment options, matching to clinical trials, and tracking and managing symptoms. Based in Boston, Massachusetts, Outcomes4Me, a woman-led company, comprises seasoned healthcare, oncology, pharmaceutical, consumer and technology veterans.

Spotlight

Life sciences is a blanket term used to describe the study of all things relative to living organisms, such as biology, physiology, and biochemistry.

Spotlight

Life sciences is a blanket term used to describe the study of all things relative to living organisms, such as biology, physiology, and biochemistry.

Related News

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

GenScript ProBio Enters into Strategic Partnership with RVAC Medicines

GenScript ProBio | February 24, 2023

GenScript ProBio, a renowned Contract Development and Manufacturing Organization (CDMO), has recently entered a strategic partnership agreement with RVAC Medicines Pte. Ltd., a biotech company specializing in the development and commercialization of mRNA vaccines and therapeutics. The collaboration is aimed at manufacturing GMP-grade plasmid DNA (pDNA) for the RVM-V001 mRNA COVID-19 vaccine candidate, as well as supporting future therapeutic pipelines. GenScript ProBio will offer GMP plasmid manufacturing service for RVAC Medicines' program, RVM-V001. By collaborating with GenScript ProBio, RVAC Medicines will be able to accelerate the clinical manufacturing of mRNA-based COVID-19 vaccines, as well as future mRNA-based vaccines designed to target other infectious diseases such as Clostriodioides difficile infection (CDI) and Respiratory syncytial virus (RSV). As RVAC proceeds with the development of its mRNA candidates, GenScript ProBio continues to offer high-quality GMP materials crucial to the objective, including plasmid DNA and the development of ancillary materials to support mRNA manufacturing processes. GenScript ProBio also provides consultative and expert guidance regarding regulatory and quality expectations of agencies worldwide. RVAC Medicines and GenScript ProBio will continue collaborating to support mRNA initiatives for both clinical and commercial stage development. Dr. Brian Min, CEO of GenScript ProBio said, "We are delighted to enter into this strategic partnership with RVAC Medicines. This collaboration will enable us to utilize our cutting-edge GMP plasmid manufacturing platform technology to support the development of mRNA-based COVID-19 vaccine and its therapeutic candidates." (Source – PR Newswire) About GenScript ProBio GenScript ProBio is a Contract Development and Manufacturing Organization (CDMO) that provides end-to-end drug discovery and commercialization services. The company's services are designed to accelerate drug development for its clients in various areas, including CGT, vaccines, biologics discovery, and antibody protein drugs. GenScript ProBio has a global presence, with subsidiaries in the Netherlands, the United States, South Korea, and China. Since October 2017, the company has helped clients in different regions, such as the United States, Europe, and Asia Pacific, to obtain over 40 IND approvals. Its goal is to drive innovation and speed up the biologics development process from target to market.

Read More

MEDTECH, INDUSTRIAL IMPACT

BioNTech to Acquire InstaDeep for Ai-Powered Drug Discovery and Development

BioNTech and InstaDeep | January 12, 2023

BioNTech and InstaDeep Ltd. recently signed an agreement wherein the former is set to acquire InstaDeep, a worldwide leader in AI and ML technologies. The acquisition involves a total upfront payment of about £362 million in cash, while BioNTech shares will be used to buy the remaining 100% of InstaDeep shares, excluding those currently held by BioNTech. The acquisition strengthens BioNTech's aim to establish world-leading abilities in AI-driven drug discovery and develop vaccines as well as next-generation immunotherapies to treat diseases with significant unmet medical needs. In addition, the company will enhance its network of worldwide research collaborators and expand its presence in many talent hubs throughout the United States, the Middle East, Africa, and Europe due to the acquisition. With the acquisition of InstaDeep, BioNTech's proven and new AI- and ML-based models will be added to all of its discovery platforms and linked to an automated lab infrastructure through InstaDeep's DeepChainTM platform. MD, CEO and Co-Founder of BioNTech, Prof. Ugur Sahin, said, "Since the inception of BioNTech, we have focused on leveraging computational solutions to create personalized immunotherapies that can reach a wide patient population." (Source: Globe Newswire) Adding to this, CEO and Co-Founder of InstaDeep, Karim Beguir, stated, "AI is progressing exponentially and our mission at InstaDeep has always been to make sure it benefits everyone. We are very excited to join forces and become one team with BioNTech, with whom we share the same culture of deep tech innovation and focus on positive human impact." (Source: Globe Newswire) About BioNTech BioNTech is a fully-integrated and worldwide leader in immunotherapy. It has been focusing on automating and digitizing processes and developing capacities for the specialized production of individual vaccinations and large-scale goods, such as the COVID-19 vaccine. As immunotherapy pioneers, the company believes that science and innovation can make a difference for humankind. Therefore, since the beginning, it has focused on harnessing the immune system's total capacity to combat cancer and infectious diseases.

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Oxford Nanopore Technologies Collaborates with UPS Healthcare

Oxford Nanopore Technologies | February 17, 2023

On February 16, 2023, Oxford Nanopore Technologies announced that it will be furthering its collaboration with UPS Healthcare to expedite the distribution of its Oxford Nanopore DNA/RNA sequencing products and consumables throughout the Asia Pacific region. The collaborative effort will strengthen the supply chain for Oxford Nanopore's portable, real-time DNA sequencing devices in key markets across Asia. By leveraging the specialized healthcare logistics solutions provided by UPS, Oxford Nanopore will be able to provide its customers with faster delivery times, simplifying the entire process and reducing customer pain points. In addition, this development will enable Oxford Nanopore's customers to allocate more time and resources toward high-impact, time-sensitive genomics research, particularly in critical areas such as human disease, cancer, and agriculture. Oxford Nanopore's flow cells will be stored at UPS Healthcare's temperature-controlled distribution facility in Singapore for the first time and will be delivered within 24 to 48 hours to destinations across the Asia Pacific via UPS's cold chain distribution capabilities. For time- and temperature-sensitive shipments, Oxford Nanopore, will additionally use UPS® Premier's premium, prioritization, tracking and recovery service. The objective will be same-day dispatch and quicker delivery of flow cells, which are consumable cartridges that include the chemistry and technology required for nanopore-based sequencing and are used in tandem with Oxford Nanopore's product range. Oxford Nanopore's investment in the Asia Pacific demonstrates the company's ongoing commitment to supporting the area's rising client base, with several genomics-led research projects prospering across region countries. They include translational cancer research, pathogen surveillance and agricultural sequencing, most notably to preserve Malaysian shrimp farming. With more than 17 million square feet of cGMP and GDP-compliant healthcare distribution space worldwide, UPS Healthcare provides scientific communities with unrivaled healthcare logistics expertise. After a fulfillment deal signed in 2022 that presently covers the United States and Canada, this is Oxford Nanopore's second region served by UPS Healthcare. Plans to expand the collaboration to other parts of the world, including Australia, are expected to be announced in 2023. About Oxford Nanopore Technologies Founded in 2005, Oxford Nanopore Technologies has made a significant breakthrough by creating the world's first and only platform for nanopore DNA and RNA sequencing. This new generation of sequencing technology offers numerous benefits, including the ability to scale to portable or ultra-high-throughput formats, real-time data delivery, and the ability to provide detailed biological data. By offering such innovative technology, Oxford Nanopore Technologies seeks to transform traditional biological analyses and explore new applications that can positively impact society. The company now has over 600 employees with expertise in a wide range of fields, including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing, and commercialization.

Read More